CD8A and cancer: Our study's finding of increased chemotherapeutic sensitivity in the low-risk group suggests that combining cisplatin with immunotherapies could enhance treatment benefits, possibly by stimulating CD8+ T cells and strengthening the anti-cancer immune response.